Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to ...

According to the University of California San Francisco, Huntington’s disease affects one in every 10,000 to 20,000 people in ...

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...

Prilenia Therapeutics is planning to file its Huntington’s disease ... HD address the symptoms of the disease, and pridopidine is vying to become the first drug approved to slow down its ...

A drug originally developed for high blood pressure could find a new use in the treatment of Huntington's disease, thanks to an artificial intelligence-based drug discovery programme at Spain's ...

ClearPoint's Q4 updates: neurosurgery growth, expanding services, controlled cash burn and high-potential partner programs driving future prospects. See more here.

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

Huntington’s disease (HD) is a progressive ... Medical treatments Doctors may prescribe medications to help manage specific symptoms: Movement symptoms: Drugs such as tetrabenazine and ...

The Orphan Drugs Market is experiencing significant growth due to increasing investment in rare disease research, regulatory incentives, and advancements in biotechnology. Orphan drugs are specialized ...